ClinicalTrials.gg
CompletedNCT04957225MIRAAUpdated Mar 9, 2023

MIRAA - Implementation of Intensive Rehabilitation of Aphasia and/or Apraxia of Speech in Swedish Healthcare

An interventional study of MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech) in Aphasia, Apraxia of Speech and Stroke, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-09.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2021, registered Jun 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Positive outcomes have been shown following intensive treatment of speech and/or language impairment post stroke, but how to design intensive treatment programs to achieve optimal recovery and neuroplasticity changes needs to be further researched. The purpose of the MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech) project is to study feasibility of intensive intervention for acquired aphasia and apraxia of speech (AOS) after stroke in the regular Swedish health-care according to the updated national guidelines from the Swedish National Board of Health and Welfare.

Read the detailed description

According to the Swedish National Board of Health and Welfare's guidelines for stroke care, persons with aphasia shall be offered intensive rehabilitation by speech-language pathologists. The aphasia rehabilitation is however sparse and unevenly distributed over the country as reported by the Swedish Aphasia Foundation. People with aphasia are seldom offered long-term treatment and intensive therapy is rarely offered. Intensive treatment is defined as at least 4h/week by the National Board of Health and Welfare, but higher intensity can be beneficial if tolerated by the patient.

Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech, MIRAA, is a modified Intensive Comprehensive Aphasia Program (ICAP) intervention program developed in the applicant's research group. MIRAA consists of a selection of evidence-based and/or well-established methods for speech and language rehabilitation as well as computer training. The training is both individual and group based, including communication between participants to promote transfer to real-life situations. Rehabilitation is based on principles that have been shown to promote neuroplasticity changes, such as high training intensity and multiple repetitions of tasks, for learning and relearning after brain injury. The intervention is goal-driven and individualized for high saliency, with focus on each participant's difficulties with language, speech and communication.

Speech and Language Pathologists (SLPs) all over Sweden working with aphasia and/or AOS following stroke are offered to participate in the study. At the time of recruitment, SLPs are invited to respond to a questionnaire about their current practice. SLPs accepting to participate are offered a 2-day workshop and recurring sessions containing introduction to and training in the MIRAA program as well as information about the logistics of the study.

42 SLPs from 23 clinics over the country participate in the study. The SLPs recruit participants with aphasia/AOS from their waiting and offer them a six-week MIRAA rehabilitation program consisting of a combination of individual treatment and group session and computer-assisted/homework training, with the goal level of 60 hours. The content of the program is individually adapted to clinics and participants. Participation in the study is consecutively offered to all individuals with speech language impairment post stroke that meet the inclusion criteria.

Following administration of the MIRAA-program including pre- and post-testing, participating SLPs will complete a questionnaire on their experiences of delivering the intensive intervention and factors hindering and facilitating implementation. Participants with aphasia/AOS and their next of kin will also provide information about their experiences through questionnaires and semi structured interviews, focus groups interviews and participant observations.

All participants are tested pre- post and at follow-up by a speech and language pathologist. Behavioral tests consist of quantitative measurements of speech, language, communication, cognition and quality of life. Part of the testing (TAX and CAT informative speech) is video- recorded for analysis after testing.

Background data are obtained noting sex, age, handedness, education level, language history aphasia type and severity and AOS, time since onset, mental fatigue, social life, number of strokes and earlier intensive rehabilitation at the time of the first assessment.

A subgroup of participants and SLPs from five clinics distributed over varying types of clinics reflecting the diversity among the clinics (inpatient care, primary care) take part in semi-structured interviews based on interview guides combined with focus group interviews and participant observations during one day of the last week of the intensive program focusing on facilitating and hindering factors for complying with an intensive intervention program like MIRAA.

A group consisting of SLPs not being able to participate in the study will form a focus group and discuss the specific factors hindering participation in the study in their respective settings.

The primary aim of this project is to explore the feasibility for national implementation of an intensive comprehensive intervention program for aphasia and AOS following stroke (MIRAA) in Swedish health care.

  • What are facilitating or hindering factors for SLPs and their patients in the subacute and chronic phase post stroke with aphasia and/or AOS to comply with an intensive intervention program like MIRAA?
  • How do participants, next of kin and SLPs experience intensive training in terms of effects and satisfaction with the program and with the implementation?

A secondary aim is to examine whether short-term and / or long-term effects on language, speech, communication and quality of life after intensive rehabilitation can be demonstrated.

  • Can treatment effects regarding speech and/or language be detected when comparing the control group with the intervention group after six weeks of intensive intervention?
  • Can treatment effects regarding communication and quality of life be detected when comparing the control group with the intervention group after six weeks of intensive intervention?
  • Can long-term treatment effects on speech, language, communication and quality of life four months post intervention be detected?
02

Conditions studied

  • Aphasia
  • Apraxia of Speech
  • Stroke

Keywords

  • Intensive rehabilitation
  • Neuroplasticity
  • Implementation in healthcare
  • Stroke guidelines
  • ICAP
  • MIRAA
03

In context

Aphasia

338 studies on the registry are indexed under Aphasia; 95 are open to participants now.

This study's enrollment of 25 is below the median of 30 across 298 interventional studies indexed under Aphasia.

Browse Aphasia studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,148 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aphasia minimum 3 months post stroke
  • Apraxia of Speech minimum 3 months post stroke
  • Being able to participate in rehabilitation in Swedish (not in need of translator to partake).

Exclusion criteria

Exclusion Criteria:

  • Severe loss of sight
  • Severe loss of hearing
  • Severe cognitive decline
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Direct intervention

    Goal level 60 hours of intensive treatment during 6 weeks. Intensive treatment of aphasia and AOS in ICAP-format (MIRAA).

    Behavioral: MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)

  • No intervention
    Waiting group

    No intervention during 6 weeks, testing directly before and after the waiting period. After the waiting period the participants receives the same intervention as the direct intervention arm.

Interventions

  • BehavioralMIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)

    Multimodal intensive treatment of aphasia and AOS

    Also known as: Modified ICAP (Intensive Comprehensive Aphasia Program)

06

What researchers measure

Primary outcomes

  1. Evaluation of training, questionnaire to participating Speech and Language Pathologists

    Minimum score 0, maximum score 12. Higher scores mean better outcome on satisfaction with intensive training and effects on speech, language and functional communication.

    Time frame: Directly after intensive treatment

  2. Evaluation of training, questionnaire to participants

    Minimum score 3, maximum score 12. Higher scores mean better outcome on satisfaction with intensive training and effects on speech, language and functional communication.

    Time frame: Directly after intensive treatment

Secondary outcomes

  1. Comprehensive Aphasia Test (CAT)

    Comprehensive Aphasia Test (CAT) language battery. Comprehension of spoken language: minimum score 0, maximum score 66; Comprehension of written language: minimum score 0, maximum score 62; Repetition: minimum score 0, maximum score 74; Naming: minimum score 0, maximum score no limit; Reading: minimum score 0, maximum score 70; Writing: minimum score 0, maximum score 76. Higher scores mean better outcome in language functions.

    Time frame: Changes from baseline in language battery scores at 6 and 16 (+-2) weeks.

  2. Boston Naming Test (BNT)

    Minimum score 0, maximum score 60. Higher scores mean better outcome in naming ability.

    Time frame: Changes from baseline scores at 6 and 16 (+-2) weeks.

  3. Rating scale for apraxia of speech (SkaFTA, Swedish version of ASRS)

    Minimum score 0, maximum score 52. Lower scores mean better outcome in speech functions.

    Time frame: Time Frame: Changes from baseline scores at 6 and 16 (+-2) weeks.

  4. Protocol for Apraxia of Speech (TAX)

    Minimum score 0, maximum score 30. Lower scores mean mean better outcome in speech functions and non verbal oral apraxia.

    Time frame: Changes from baseline scores at 6 and 16 (+-2) weeks.

  5. Comprehensive Aphasia Test (CAT), subtest cognitive screening

    Minimum score 0, maximum score 38. Higher scores mean better outcome in cognitive functions.

    Time frame: Changes from baseline scores at 6 and 16 (+-2) weeks.

  6. Communicative Effectiveness Index (CETI)

    Minimum score 0, maximum score 100. Higher scores mean better outcome in communicative effectiveness.

    Time frame: Changes from baseline scores at 6 and 16 (+-2) weeks.

  7. General Health Questionnaire 12 questions (GHQ-12)

    Minimum score 0, maximum score 36. Lower scores mean mean better outcome in general health.

    Time frame: Changes from baseline scores at 6 and 16 (+-2) weeks.

07

Study locations

1 site
  • Karolinska Institutet, CLINTEC, Division of Speech and Language Pathology, F67, Karolinska University Hospital, Huddinge
    Stockholm, 141 86, Sweden
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual patient data (IPD) that underlie results in a publication.

Supporting information: Study protocol, Informed consent form

Time frame: 2021-2031

Access criteria: Swedish National Data Service open source

Data sharing details ↗ · snd.gu.se

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Dec 2022, 21 months.

Of 183 non-industry interventional studies with no phase under Aphasia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's 21 months is below that.

Counting every sponsor, half of 185 studies reached it within 36 months; a quarter within 20 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jul 12, 2021
StartActual
Mar 10, 2021
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Last update
Mar 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04957225
Responsible party
Ellika Schalling (Associate professor, Speech Language Pathologist, Karolinska Institutet) — Principal investigator
First posted
Jul 12, 2021
Start date
Mar 10, 2021
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Mar 9, 2023

Study contacts

Ellika Schalling, Ph.D, SLP
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion